Follow The Filings

URGN Urogen Pharma Ltd.

Health Care, filed as UROGEN PHARMA LTD (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 2

  • 4 Owners
  • Max 4.8%
  • $59M
  • 1 new 1 reduce 1 exit 1 small

In 2026 Q2 Polen Capital Management opened a position in Urogen Pharma, Cathie Wood trimmed, and Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 4.8% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 4.8%
  2. Palo Alto Investors 0.12%
  3. Cathie Wood Reduce 0.02%
  4. Polen Capital Management New 0.01%

Who owns URGN

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 4.8%, was 3.4% Small add +0.7% 1,439,996 $53M History
Cathie Wood, Ark Investment Management 0.02% Reduce −12.1% 101,508 $3.7M History
Polen Capital Management 0.01% New 0.01% 29,615 $1.1M History
Palo Alto Investors 0.12% Hold 24,500 $902K History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 11,000 $198K History

4 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by URGN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All URGN insider trades
  • None no insider bought on the open market
  • $2.9M sold by 1 insider outside a trading plan
  • $1.3M sold by 1 insider under 10b5-1 plans
  1. Mark Schoenberg Chief Medical Officer
    Sale
    $2.9M 60,677 shares at $47.05 51% of stake
    Traded Aug 20 Filed Aug 24
    ↗
  2. Mark Schoenberg Chief Medical Officer
    Planned sale
    $400K 10,000 shares at $40.00 7.7% of stake
    Traded Jul 9 Filed Jul 10
    ↗
  3. Mark Schoenberg Chief Medical Officer
    Planned sale
    $350K 10,000 shares at $35.01 7.2% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  4. Mark Schoenberg Chief Medical Officer
    Planned sale
    $300K 10,000 shares at $30.00 6.9% of stake
    Traded May 8 Filed May 11
    ↗
  5. Mark Schoenberg Chief Medical Officer
    Planned sale
    $250K 10,000 shares at $25.00 6.7% of stake
    Traded Nov 19, 2025 Filed Nov 20, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 17 option exercises and 10 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 3.03,5.02,5.07,9.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
DEF 14A FORM DEF 14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,2.03 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K FORM 10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $82.71M $90.4M $109.79M
Gross profit $73.35M $81.52M $97.34M
Gross margin * 88.7% 90.2% 88.7%
Net income -$102.24M -$126.87M -$153.49M
Net margin * -123.6% -140.4% -139.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $169.19M $276.14M $186.02M
Total non-current assets * $9.12M $9.58M $14.43M
Total assets $178.31M $285.71M $200.46M
Total current liabilities $31.21M $45.95M $46.42M
Total non-current liabilities * $212.31M $248.56M $259.51M
Total equity -$65.21M -$8.8M -$105.47M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$76.38M -$96.77M -$162.44M
Cash from investing -$0.953M -$20.61M $61.56M
Cash from financing $116.93M $194.62M $39.92M
Net change in cash $39.6M $77.24M -$60.97M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.